• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to new 10-halo-E-homoeburnane derivatives of the general formula (I), <IMAGE> (I) wherein R2 is a C1-6 alkyl group and X is halogen, and epimers, optically active derivatives and pharmaceutically acceptable acid addition salts thereof. These substances exert vasodilating effects and can be applied to advantage in the therapy. The new compounds are prepared so that a racemic or optically active 9-halo-octahydroindoloquinolisine derivative of the general formula (II), <IMAGE> (II) wherein R2 and X are as defined above and R1 is a C1-6 alkyl group, or an acid addition salt thereof is treated with a strong base, and, if desired, the 15-epimers of the resulting compound having the general formula (I) are separated from each other, and/or, if desired, the resulting substance is converted into its pharmaceutically acceptable acid addition salt and/or resolved.
    公开号:SU993819A3
    申请号:SU802957550
    申请日:1980-08-12
    公开日:1983-01-30
    发明作者:Сантаи Чаба；Сабо Лайош；Калауш Дьердь；Данчи Лайош；Кеве Тибор；Дрекслер Ференц
    申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    (54) THE METHOD OF OBTAINING 1O-BROM-14-OXA-1 & YUKSI-YOHHEMOEBURNAN OR ITS-15 EPIMERS 366 of preparative thin-layer chromatography. Compound (I) is obtained in well identifiable form. Their structure is uniquely proved by the position of the bands of characteristic groups in the IR spectrum, NMR signals, and mass spectrometry values. The effect of compounds (I) on blood circulation is studied. The studies were performed on narcotized baths using chloralose-urethane sob. Arterial blood pressure, pulse rate, blood flow in Arteri ewora8is and DKeH carotis in-terna, a. also vascular resistance in both vascular areas (vascular constriction — blood pressure: blood flow in the corresponding vascular tracts). Aqueous solution of substances is administered intravenously at a dose of 1 mg / kg body weight. 5-6 experiments were performed per substance. Vincamine is used as a standard. Comparative experiments are presented in the following tables. Meaning of abbreviations; MABR - mean arterial pressure, mm Hg. v .; NR pulse frequency, min; CB F - schyuvotok in AHeriq cartHs interpa ml-mshg; CVR - vascular ss plenivlenie in the region of Arterie cqroiiS IvttertwMMpr.CT min / ml F B F - blood flow in Arteria femorus ls, ml FVR - vascular. resistance in the area / 4rteria feworctEis mm Hg. Art. min / ml 1. Table 1 shows the effect of 1Obrom-14-pKco-i 5-hydroxy-E-goms burr on. (3 ti, 17 ct) on blood circulation. I In tab. 2 shows the effect of Vincamine on blood circulation. From these tables it can be seen that 10-bromo-14-scso-15-hydroxy-E-homoeburnan (3 I, 17 ct), administered intravenously at a dose of 1 mg / kg to narcotic dogs, has virtually no effect on the pressure and pulse rate, i.e. . its systemic effect on the circulation is insignificant. In the vascular region of the caroiis tntcrnd, the compound causes a 25% dilation of the vessels, which corresponds to a 21% increase in blood flow. However, the compound practically does not squeeze any other effect on Kjjyr circulation. The compounds of the general formula (1), due to their vasodilating action, are suitable for use in medicine. The biologically active substances of the general formula (I) can be shifted with the usual in the pharmaceutical industry, suitable for parenteral or enteric administration, non-toxic, inert solid or liquid carriers and / or excipients and formulations into drugs. As carriers, for example, water, gelatin, lactose, milk sugar, starch, pectin, magnesium stearate, stearic acid, talc can be used. vegetable oils (peanut oil, olive oil, etc.). Biologically active substances can be molded, for example, in the form of solid drugs (round or square tablets, dragees, capsules, for example, hard gelatin pills, etc.) or in the form of liquid drugs (oil or aqueous solutions, suspensions, emulsions, syrups soft gelatinous capsules administered by injection). The amount of solid carrier in a single dose may vary within wide limits and is preferably 0.025-1 g. Preparations may also contain, under lime conditions, also usual pharmaceutical auxiliaries, for example, preservatives, wetting agents, emulsifiers, salts for establishing osmotic pressure, buffers, flavoring agents, etc. Preparations under known conditions may also contain other known compounds with pharmaceutical action. Preparations are preferably molded in advanced doses that are suitable for the desired method of use (in (D). Preparations are prepared, for example, by sieving, displacing, granulating, pressing or dissolving. Preparations are also subjected to other treatments common in the pharmacological industry (for example, sterilization.) Example 1, 10-bromo-14-oxo-15-hydroxy-E-homoeburnan (3 at 17 ot.) To suspension 3, O g (6.9 mmol) 9-bromo-1 d-ethyl-1 2-hydroxy-2- (methoxycarbonyl) -ethyl} -1,2,3,4,5,6,7,12-octagvdro-12- to -H-indole (2,3-a) -hrshulisin in 200 ml anhydrous toluene and 2.8 m 0.30 g (2.7 mmol) of potassium ter-p-butylate was added to a liter (2.6 g) of acetophenone. The reaction mixture was kilt with a reflux condenser for 4 hours under argon atmosphere and under intense The mixture is then cooled to 0 ° C. and shaken 4 times with 30 ml of cold 2.5% aqueous sulfuric acid. The combined aqueous phases of oxygen are basified with 25% aqueous ammonia to pH 10 and then extracted three times with 30 ml dichloromethane. The organic phases are dried over magnesium sulfate, filtered, the filtrate is evaporated in vacuo and the residue is recrystallized from 10 ml of methanol. 1.85 g (66.6%) of the product is produced as a mixture of epimers. M.p. 206-2О8 С. The total formula is С5.оН2зВгМ2 О2 (mol. Weight 403.33). I A mixture of epimers is separated using preparative thin layer chromatography. A silica gel plate + 364 P measuring 2OX2O 1.5 mm serves as an adsorbent, a mixture of benzene and methanol prepared in 14: 3 ratio is used as an eluent. The product is eluted with dichloromethane. Epimer A recrystallized from 5 ml, epimer B from 10 ml of methanol. About 4 g of epimer A is obtained from the top spot. Yield 21.6%. T. pl. 177178 C. 6 IR spectrum (KBG), cm 34OO (-JOH), 1660 (amide-CO). Mass spectrum (): 404, 4ОЗ, 4О2, 401, 376, 36Q, 358, 347, 346, 332, 330, 317, 315, 303, 301, 277, 275, 180, 167, 153, 14О, From the bottom , pt and they produce 1.25 g of epnmer B. V'kots 67.6%, T. pl.214-216 “C. HK-cneKip (KBir), cm-340O (-OH) D 1685 (sh. Id-CO) 1. Mass spectrum (p / e): 404, 4OZ, 402, 401, 376, 374, 360, 358, 347, 345, 332, 330, 303, 301, 277, 275, 180, 167, 153, 14O. NMR spectrum (deuterochloroform): O, 96 (three, 3N, -CH) 7.39-8.24 (multiplet, 3N, aroma, H); , 51 ppm; E., Yu, 2 Hz; steam C -, - 1 - H 7.39 ppm. 11.12 8.7 Hz (ortho) 8.24 ppm; 3-, d 2.8 Hz Lyta). Table 1
    Formula of invention
    The method of obtaining 1O-bromo-14-oxo-15 h xi-Bngomoeb; group of formula Br
    irt
    „: M
     , “BUT SHS it is C-15 etasmercis, which is also distinguished by the fact that 9-ramoctagidroindolquinolizcn formulas
    HD-dH-dHt Kx
    foOBi
    de R - C "" alkyl,
    is treated with an alkali metal alkanol and the obtained target compound is isolated or separated by cd epim &amp;
    Sources of information taken into account in the examination
    1. The patent of Germany No. 2222186, cl. C O7 D 471/22, published on 30.06.77.
    2. Carrer P. The course of organic chemistry. L., 1960 p. 116.
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining 1O-bromo-14 — oxo15-hydroxy-E-homoeburnan of the formula
    Br
    I
    HO 8 where R ^ - C l - Cs ^ alkyl, is treated with an alkali metal alcoholate and the obtained target compound is isolated or separated into epimers.
    or its C-15 epimers, characterized in that 9-bromoctahydroindolequinolizine of the general formula
    类似技术:
    公开号 | 公开日 | 专利标题
    US4072759A|1978-02-07|Novel benzylalcohol derivatives as antidiabetics and cardiotonics
    BG60411B2|1995-02-28|Bis-dimethoxymethyl|isoquinoline salts, method for their preparation and pharmaceutical compositions containing them
    JPH05208957A|1993-08-20|New r-and s-carbazole derivatives
    US4556662A|1985-12-03|Bispidine derivatives and antiarrhythmic compositions
    US4035370A|1977-07-12|Alkaloid esters
    SU993819A3|1983-01-30|Process for preparing 10-bromo-14-oxo-15-hydroxy-e-homoeburnane or its c15 epimers
    IE50471B1|1986-04-30|Substituted oxocarboxylic acids,processes for their preparations,their use and medicaments containing them
    US4528289A|1985-07-09|Corynantheine derivates, processes for their preparation, and their use
    US4455307A|1984-06-19|Antihypertensive use of triazolobenzodiazepines
    SU841589A3|1981-06-23|Method lf preparing hexahydro-gamma-carbolines or their salts
    US4057551A|1977-11-08|Indolo[2,3-a]quinolizines
    SU1241989A3|1986-06-30|Method of producing |-2-/1-|ethyl/-1,3-diazacyclopentene-2 or hydrochloride thereof
    US4341789A|1982-07-27|Cycloaliphatic prostaglandin analogues
    HU180929B|1983-05-30|Process for producing new bromo-vincamone derivatives
    CA1066706A|1979-11-20|14,15-dihydro-eburnamenine compounds
    US3328424A|1967-06-27|1-isopropylamino-2-hydroxy-3-|-propane and salts thereof
    US4235903A|1980-11-25|1-Hydroxyalkanamine tetrahydrocarbazoles and cyclopent[b]indoles, compositions and method of use
    US3423425A|1969-01-21|11-aminoaliphatic - 5,10 - methanodibenzo|cycloheptadienes and the salts thereof
    US4476127A|1984-10-09|7-Diethylamino-5-methyl-thiazolo[5,4-d]pyrimidine and pharmaceutical composition containing same
    US4201790A|1980-05-06|Benzophenone derivatives
    JP2577994B2|1997-02-05|Cerebral blood flow enhancer
    US4173583A|1979-11-06|Diastereoisomers of 5-|ethyl)salicylamide
    US3369029A|1968-02-13|3-guanidino-alkylene-chromans
    US4548947A|1985-10-22|1-|-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia
    US4839362A|1989-06-13|Eburnamenine derivatives, pharmaceutical compositions and methods employing them and processes for their preparation
    同族专利:
    公开号 | 公开日
    NL8004565A|1981-02-17|
    NO153730B|1986-02-03|
    JPH0227353B2|1990-06-15|
    BE884472A|1981-01-26|
    IL60827D0|1980-10-26|
    FI67382C|1985-03-11|
    SE436881B|1985-01-28|
    DK348080A|1981-02-14|
    ES8106517A1|1981-08-01|
    NO802403L|1981-02-16|
    FI802535A|1981-02-14|
    AT375940B|1984-09-25|
    US4285950A|1981-08-25|
    IT1132404B|1986-07-02|
    NZ194654A|1982-12-07|
    SE8005687L|1981-02-14|
    CA1140121A|1983-01-25|
    GB2058759B|1983-07-06|
    IL60827A|1983-07-31|
    DK154431B|1988-11-14|
    GB2058759A|1981-04-15|
    HU181496B|1983-07-28|
    IT8024151D0|1980-08-13|
    ATA412780A|1984-02-15|
    DK154431C|1989-04-10|
    NO153730C|1986-05-14|
    CH644123A5|1984-07-13|
    FI67382B|1984-11-30|
    FR2463141B1|1983-11-10|
    FR2463141A1|1981-02-20|
    JPS5629590A|1981-03-24|
    ZA804922B|1981-08-26|
    AU6137080A|1981-02-19|
    PH16023A|1983-05-30|
    DE3026584A1|1981-05-07|
    AU541869B2|1985-01-24|
    ES494211A0|1981-08-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3770724A|1970-03-31|1973-11-06|Roussel Uclaf|Process for preparing pentacyclic alkaloids|
    FR2206090B1|1972-11-16|1975-11-28|Omnium Chimique Sa|
    GB2010833B|1977-11-25|1982-04-15|Scras|Homoerburnamine preparation|
    DE2922316A1|1978-06-12|1979-12-20|Omnium Chimique Sa|NEW HALOGEN DERIVATIVES OF VINCAMINE, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT|
    HU177732B|1978-12-15|1981-12-28|Richter Gedeon Vegyeszet|Process for producing 10-bromo-vincamine and acid additional salts thereof,and 10-bromo-14-epivincamine|
    HU180927B|1979-07-13|1983-05-30|Richter Gedeon Vegyeszet|Process for producing 1k-hydroximino-e-homoe-eburane de rivatives|HU180927B|1979-07-13|1983-05-30|Richter Gedeon Vegyeszet|Process for producing 1k-hydroximino-e-homoe-eburane de rivatives|
    HU180929B|1979-08-13|1983-05-30|Richter Gedeon Vegyeszet|Process for producing new bromo-vincamone derivatives|
    FR2487836B1|1980-07-31|1983-07-29|Richter Gedeon Vegyeszet|
    HU190399B|1982-06-30|1986-08-28|Richter Gedeon Vegyeszeti Gyar Rt,Hu|Process for the production of e-homo-eburnane-derivatives|
    AT383599B|1982-06-30|1987-07-27|Richter Gedeon Vegyeszet|Process for the preparation of novel racemic and optically active E-homo-eburnane derivatives and of acid addition salts thereof|
    US4481204A|1983-06-29|1984-11-06|Richter Gedeon Vegyeszeti Gyar R.T.|E-Homo-eburnane derivatives, process for their preparation, and pharmaceutical compositions containing these compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU79RI723A|HU181496B|1979-08-13|1979-08-13|Process for preparing 10-bromo-15-hydroxy-e-homo-eburnanes|
    [返回顶部]